- in 2006 by Pfizer, but poor
sales led
Pfizer to
withdraw it in 2007.
Afrezza, a
monomeric inhaled,
ultra rapid-acting
insulin developed by Mannkind...
- inhaler, upon
which was
developed its lead product,
Afrezza (inhalable insulin). The FDA
approved Afrezza on June 27, 2014. On
August 11, 2014
MannKind entered...
-
Control with
Afrezza® Rapid-acting
Inhaled Insulin".
Afrezza.
Retrieved 23
February 2025. "MannKind
Corporation Announces FDA
Approval of
AFREZZA(R); A Novel...
- ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza Oral
Insulin tregopil†...
- ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza Oral
Insulin tregopil†...
- ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza Oral
Insulin tregopil†...
- mellitus.
Admelog (insulin lispro), for type 1 and type 2
diabetes mellitus.
Afrezza (Inhalable insulin), for type 1 and type 2
diabetes mellitus.
Amaryl (Glimepiride)...
- ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza Oral
Insulin tregopil†...
- ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza Oral
Insulin tregopil†...
- ultra-long-acting
Insulin degludec# (+insulin aspart, +liraglutide)
Insulin icodec† (+semaglutide)
inhalable Exubera‡
Afrezza Oral
Insulin tregopil†...
